Mankind Pharma Limited share price
NSE: MANKIND · ISIN INE634S01028
Key numbers
- Market cap
- ₹ 1,02,212 Cr
- Current price
- ₹ 2,474.90
- 52-week high / low
- ₹ 2,642 / 1,910
- Stock P/E
- 50.0
- Book value
- ₹ 394.9
- Dividend yield
- 0.08%
- ROCE
- 13.1%
- ROE
- 12.5%
- Debt to equity
- 0.39
- Sales growth (3 yrs)
- 17.7%
- Profit growth (3 yrs)
- 14.3%
- 1-year return
- -3.5%
About Mankind Pharma Limited
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 3,079 | 3,570 | 3,567 | 3,443 | 4,031 |
| Operating profit | 683 | 847 | 919 | 930 | 1,056 |
| Net profit | 421 | 438 | 409 | 554 | 568 |
| EPS (₹) | 10.20 | 10.62 | 9.90 | 13.44 | 13.76 |
Concall summary (2026-08-04)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Our revenue from operations during quarter 1 FY 2027 has increased by 12.9% year -on-year basis to INR4,031 crores as compared to INR3,570 crores in quarter 1 FY26.
- This 2.4% is lower than our guidance of 2.8% to 3% for the full year FY27.
Growth & demand
- The secondary sales as per IQVIA grew 12.7% during the quarter, led by healthy volume growth of 4.7%, which increased by 220 bps year -on-year.
- Despite softer growth, we gained market share in key brands Manforce, Preganews, Gas-o-fast. also, our modern trade and e-commerce share increased to 15% from 11% a year ago, supported by 38% growth in that channel.
Margins & costs
- During the quarter, overall revenue increased to INR4,031 crores, up 13% year -on-year with EBITDA of INR1,060 crores and EBITDA margin improving by 250 bps year-on-year to 26.3%.
- Our gross margins for the quarter has increased by 230 basis point year-on-year basis to 72.8% from 70.5% in quarter 1 FY26 and 60 basis point increase on quarter -on- basis.
Capex & expansion
- Our capex spend during the quarter has increased to INR198 crores in quarter 1 FY27 as compared to INR127 crores in quarter 1 FY26.
- The capex as a percentage of revenue is 4.9% of the total revenue, which is lower than our guidance of 6% to 7% of revenue for FY27.
Balance sheet & cash
- 230 basis point increase is from the gross margin expansion and the balance 20 basis point benefit has come from the operating leverage.
- In quarter 1 FY27, our cash flow to EBITDA ratio has decreased to 77% as compared to 99% in quarter 1 FY26.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.